Still Eyeing IPO, Quark Says Cost Expectations for Rx Pipeline Exceed $54M

The company hopes to raise enough capital in the IPO to pay for that bill, which covers phase I and II trials for its lead candidates. It also said R&D costs decreased over the first nine months of 2010 while revenues rose for the period year over year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories